Clinical Trial Goal
To find out:
- The highest dose of SX-682 that’s safe to give
- If SX-682, with or without decitabine, is safe and works well to treat MDS that is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have MDS that is refractory after at least 1 month of treatment with azacitidine, decitabine or a similar drug
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Decitabine is a hypomethylating agent that blocks the growth of cancer cells.
SX-682 is a small molecule inhibitor that blocks CXCR1 and CXCR2 in certain cells.
You'll be placed in 1 of 2 groups:
SX-682 is a small molecule inhibitor that blocks CXCR1 and CXCR2 in certain cells.
You'll be placed in 1 of 2 groups:
- Group 1 – SX-682
- Group 2 – SX-682 plus decitabine
You’ll get:
- Decitabine - Group 2 only - A pill that you take by mouth
- SX-682 – A pill that you take by mouth 2 times each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for as long as you're in the trial.
The Food and Drug Administration (FDA) has not yet approved SX-682.
Locations
Sponsors
collaborator: H. Lee Moffitt Cancer Center and Research Institute, collaborator: National Heart, Lung, and Blood Institute (NHLBI), collaborator: AdventHealth, collaborator: Emory University, collaborator: University of Miami, collaborator: Mayo Clinic, collaborator: Montefiore Medical Center, collaborator: National Cancer Institute (NCI), collaborator: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, lead: Syntrix Biosystems, Inc.
